Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation

Homoharringtonine (HHT), an Food and Drug Administration (FDA)-approved anti-leukemia drug, exerts anti-tumor activity in several solid tumors, including colorectal cancer (CRC). However, its mechanism of action in CRC progression has not been comprehensively elucidated. The drug-disease targets wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Muwen, Li, Junyi, Yuan, Lingling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810123/
https://www.ncbi.nlm.nih.gov/pubmed/34847838
http://dx.doi.org/10.1080/21655979.2021.2012626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810123/
https://www.ncbi.nlm.nih.gov/pubmed/34847838
http://dx.doi.org/10.1080/21655979.2021.2012626

Ejemplares similares